The prevalence of metabolic syndrome in male patients of early onset androgenic alopecia compared to age matched controls
Keywords:Androgenetic alopecia, Metabolic syndrome, Diastolic blood pressure, Trichoscopy
Background: Androgenic alopecia is most common type of non-scarring alopecia in men. It is associated with high risk of cardiovascular events. Aim was to study the prevalence of metabolic syndrome in male patients of early onset androgenic alopecia.
Methods: A case-control study was conducted at the dermatology out-patient department over a period of 6 months which included 100 patients of androgenic alopecia and 100 age matched controls. All subjects were aged 20 to 35 years and underwent detailed history, clinical examination including trichoscopic examination and measurement of waist circumference and blood pressure. Fasting blood sugar, triglyceride and high-density lipoproteins were tested following overnight fasting. Diagnosis of metabolic syndrome was based on criteria of national cholesterol education program (NCEP) adult treatment panel III. Chi square test was used as a test of significance. P value <0.05 was considered statistically significant.
Results: Prevalence of metabolic syndrome was more in androgenic alopecia patients than in controls (48% versus 18%, p value <0.001). Androgenic alopecia patients had higher prevalence of increased waist circumference (76% versus 28%, p value <0.0001), increased diastolic blood pressure (32% versus 12%, p value=0.007), increased serum triglycerides (46% versus 24%, p value=0.0011) and decreased serum high-density lipoproteins (36% versus 18%, p value=0.0042) compared to controls.
Conclusions: Early screening for metabolic syndrome and its components is beneficial in patients with androgenic alopecia to reduce cardiovascular mortality.
Gopinath H, Upadya GM. Metabolic syndrome in androgenic alopecia. Indian J Dermatol Venerol Leprol. 2016;82:404-8.
Acibucu F, Kayatas M, Candan F. The association of insulin resistance and metabolic syndrome in early androgenic alopecia. Singapore Med J. 2010;51:931-6.
Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;215-25.
Fultop T, Tessier D, Carpentier A. The Metabolic Syndrome. Pathologie Biologie. 2006;54:375-86.
Swaroop MR, Kumar BM, Sathyanarayana BD, Yogesh D, Raghavendra JC, Kumari P. The association of metabolic syndrome and insulin resistance in early-onset androgenetic alopecia in males: A case–control study. Indian J Dermatol. 2019;64:23-7.
Paul L. Huang A comprehensive definition for metabolic syndrome Dis Model Mech. 2009;2(5-6):231-7.
Daniel WW. Biostatistics: a foundation for analysis in the health sciences. 7th edition. New York: John Wiley & Sons. 1999.
Eberly LE, Prineas R, Cohen JD, Vazquez G, Zhi X, Neaton JD, et al. Metabolic syndrome: Risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care. 2006;29:123-30.
Kibar M, Aktan S, Bilgin M. Scalp dermatoscopic findings in androgenetic alopecia and their relations with disease severity. Ann Dermatol. 2014;26(4):478-84.
Vora RV, Kota RKSK, Singhal RR, Anjaneyan G. Clinical Profile of Androgenic Alopecia and Its Association with Cardiovascular Risk Factors. Indian J Dermatol. 2019;64(1):19-22.
Nabaie L, Kavand S, Robati RM. Androgenic alopecia and insulin resistance: are they really related? Clin Exp Dermatol. 2009;34(6):694-7.
Kumar K C, Kumar YH, Neladimmanahally V. Association of early-onset androgenetic alopecia with metabolic syndrome: A case–control study on 46 patients in a tertiary care hospital in South India. Indian J Paediatr Dermatol. 2019;20:25-8.